Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could tame tough eczema in phase 2 trial

NCT ID NCT07167758

Disease control Sponsor: Triveni Bio Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called TRIV-509 in 95 adults with moderate to severe atopic dermatitis (eczema). Participants receive four doses of either TRIV-509 or a placebo, then switch to the other group. The goal is to see if TRIV-509 improves eczema symptoms and is safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TRIV-509 (an experimental drug given as a shot under the skin)
What this could lead to
If successful, this could point toward a new treatment option for people with moderate to severe eczema that is not well controlled by current therapies.
What could go wrong
This is an early Phase 2a study with only 95 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

95 people

The number who actually took part.

Started

Aug 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has Atopic Dermatitis. * Has moderate to severe, active and symptomatic AD Exclusion Criteria: * Severe or uncontrolled medical conditions. * Use of topical treatments, phototherapy, systemic immunosuppressives or immunomodulatory therapies, or immunomodulatory biologics, within stated washout periods.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Triveni Bio Site #1

    Camp Hill, Pennsylvania, 17011, United States

  • Triveni Bio Site #10

    South Bend, Indiana, 46617, United States

  • Triveni Bio Site #11

    Fountain Valley, California, 17271, United States

  • Triveni Bio Site #12

    Niagara Falls, Ontario, L2H 1H5, Canada

  • Triveni Bio Site #13

    Ajax, Ontario, L1S 7K8, Canada

  • Triveni Bio Site #15

    North York, Ontario, M2N 3A6, Canada

  • Triveni Bio Site #16

    Bellaire, Texas, 77401, United States

  • Triveni Bio Site #17

    Newmarket, Ontario, L3Y 5G8, Canada

  • Triveni Bio Site #18

    Kyiv, 01135, Ukraine

  • Triveni Bio Site #21

    Prague, 11000, Czechia

  • Triveni Bio Site #22

    Ostrava, 70200, Czechia

  • Triveni Bio Site #23

    Prague, 15000, Czechia

  • Triveni Bio Site #24

    Chorzów, Silesian Voivodeship, 41-500, Poland

  • Triveni Bio Site #25

    Katowice, Silesian Voivodeship, 4-600, Poland

  • Triveni Bio Site #26

    Poznan, Wielkopolska, 61-731, Poland

  • Triveni Bio Site #27

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Triveni Bio Site #28

    Warsaw, Masovian Voivodeship, 00-872, Poland

  • Triveni Bio Site #29

    Sosnowiec, 41-200, Poland

  • Triveni Bio Site #3

    Miami, Florida, 33016, United States

  • Triveni Bio Site #30

    Poznan, Wielkopolska, 60-309, Poland

  • Triveni Bio Site #31

    Pardubice, 530 02, Czechia

  • Triveni Bio Site #33

    Wroclaw, Lower Silesian Voivodeship, 51-604, Poland

  • Triveni Bio Site #34

    Budapest, 1066, Hungary

  • Triveni Bio Site #37

    Prague, 13000, Czechia

  • Triveni Bio Site #38

    Pleven, 5800, Bulgaria

  • Triveni Bio Site #39

    Sofia, 1172, Bulgaria

  • Triveni Bio Site #4

    San Diego, California, 92123, United States

  • Triveni Bio Site #41

    Budapest, 1033, Hungary

  • Triveni Bio Site #43

    Debrecen, 4032, Hungary

  • Triveni Bio Site #5

    Dallas, Texas, 75230, United States

  • Triveni Bio Site #6

    Indianapolis, Indiana, 46250, United States

  • Triveni Bio Site #8

    Spokane, Washington, 99202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.